Pirb Inhibitors
The class of Pirb inhibitors encompasses a diverse set of chemical compounds designed to modulate the activity of Pirb, a receptor involved in immune regulation and cellular responses. These inhibitors act through various mechanisms, targeting key signaling pathways such as PI3K/Akt, MAPK/ERK, JAK/STAT, and TGF-β, which are implicated in Pirb function. LY294002 and Wortmannin are potent inhibitors of PI3-kinase, disrupting the PI3K/Akt signaling pathway. This interference leads to downstream effects on pathways associated with Pirb activity, influencing its cellular functions. SB203580 and U0126 target p38 MAP kinase and MEK1/MEK2, respectively, components of the MAPK/ERK signaling pathway. Inhibition of these kinases may impact cellular processes linked to Pirb modulation. PD98059, an inhibitor of MEK1, specifically disrupts the MAPK/ERK pathway, providing another avenue for modulating Pirb activity. Rapamycin, a mTOR inhibitor, influences the mTOR pathway, affecting cell growth and proliferation and influencing Pirb function indirectly.
SB431542 and LY364947 selectively inhibit the TGF-β receptor, suggesting an indirect inhibitory effect on Pirb by interfering with TGF-β signaling pathways. AG490 and SP0101 target JAK2 and STAT3, respectively, within the JAK/STAT pathway, providing means to modulate Pirb activity through this critical signaling cascade. SP600125, a JNK inhibitor, offers another avenue for influencing Pirb activity by targeting the JNK signaling pathway. GDC-0941, a pan-PI3K inhibitor, broadens the scope of PI3K inhibition, impacting multiple isoforms and downstream pathways associated with Pirb modulation. In conclusion, the diverse mechanisms of action exhibited by these Pirb inhibitors present promising avenues for further research into their specific impacts on immune regulation and cellular responses.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of PI3-kinase, a key enzyme in the PI3K/Akt signaling pathway. By targeting PI3-kinase, LY294002 can modulate downstream signaling events, potentially influencing pathways related to Pirb activity and its cellular functions. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase, a component of the MAPK signaling pathway. Inhibition of p38 MAP kinase by SB203580 may impact cellular processes linked to Pirb modulation, suggesting a potential indirect inhibitory effect on Pirb activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is an inhibitor of PI3-kinase, similar to LY294002. By targeting PI3-kinase, Wortmannin can disrupt downstream signaling cascades, potentially influencing pathways associated with Pirb function and contributing to its modulation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a specific inhibitor of MEK1, a kinase involved in the MAPK/ERK signaling pathway. Inhibition of MEK1 by PD98059 can affect downstream signaling events, potentially impacting pathways associated with Pirb activity and cellular functions. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an inhibitor of the mTOR pathway, a critical regulator of cell growth and proliferation. By targeting mTOR, Rapamycin can modulate cellular processes linked to Pirb function, suggesting a potential indirect inhibitory effect on Pirb activity. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542 is a selective inhibitor of the TGF-β receptor, targeting the TGF-β signaling pathway. Inhibition of the TGF-β receptor by SB431542 may impact cellular processes linked to Pirb modulation, suggesting a potential indirect inhibitory effect on Pirb activity. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
Tyrphostin B42 is a JAK2 inhibitor, targeting the JAK/STAT signaling pathway. By inhibiting JAK2, AG490 can modulate downstream signaling events, potentially influencing pathways associated with Pirb activity and its cellular functions. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a selective inhibitor of JNK, a kinase involved in the JNK signaling pathway. Inhibition of JNK by SP600125 can affect downstream signaling events, potentially impacting pathways associated with Pirb activity and cellular functions. | ||||||
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $105.00 $153.00 | 4 | |
LY364947 is a selective inhibitor of the TGF-β receptor, similar to SB431542. By inhibiting the TGF-β receptor, LY364947 may impact cellular processes linked to Pirb modulation, suggesting a potential indirect inhibitory effect on Pirb activity. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $184.00 $195.00 | 2 | |
GDC-0941 is a pan-PI3K inhibitor, targeting multiple isoforms of PI3-kinase. By inhibiting PI3-kinase, GDC-0941 can disrupt downstream signaling cascades, potentially influencing pathways associated with Pirb activity and cellular functions. | ||||||